Liquidia Technologies Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Morrisville, n.c., april 02, 2024 (globe newswire) -- liquidia corporation (nasdaq: lqda) (liquidia or the company) announced today that dr. roger jeffs, chief executive officer, and micheal kaseta, chief operating officer and chief financial officer, will provide an overview and update on the company's business during a fireside chat session at the 23rd annual needham virtual healthcare conference on tuesday, april 9, 2024, beginning at 1:30 p.m. eastern time.

Morrisville, n.c., april 01, 2024 (globe newswire) -- liquidia corporation (nasdaq: lqda) (liquidia or the company) announced today that on march 28, judge andrews of the u.s. district court for the district of delaware (district court) has set aside the injunction that was issued in august 2022 in the lawsuit filed by united therapeutics (uthr) in case no. 1:20-cv-00755-rga (the original hatch-waxman litigation). as a result, the u.s. food and drug administration (fda) is no longer enjoined from issuing final approval of liquidia's new drug application (nda) for yutrepia™ (treprostinil) inhalation powder.

Morrisville, n.c., march 13, 2024 (globe newswire) -- liquidia corporation (nasdaq: lqda) (liquidia or the company) today reported financial results for the full year ended december 31, 2023. the company will host a webcast at 8:30 a.m. et to discuss the 2023 financial results and provide a corporate update.

Morrisville, n.c., march 06, 2024 (globe newswire) -- liquidia corporation (nasdaq: lqda) announced today that it will report its full year 2023 financial results on wednesday, march 13, 2024. the company will host a webcast at 8:30 a.m. eastern time to discuss financial results and provide a corporate update.

Morrisville, n.c., jan. 30, 2024 (globe newswire) -- liquidia corporation (nasdaq: lqda) (liquidia or the company) today announced that the company will present data from the l606 clinical program at the pulmonary vascular research institute (pvri) 2024 annual congress to be held january 31 through february 3, 2024, in london, england. l606 is an investigational, sustained-release formulation of treprostinil administered twice-daily to treat patients diagnosed with pulmonary arterial hypertension (pah) and pulmonary hypertension associated with interstitial lung disease (ph-ild).

MORRISVILLE, N.C., April 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that Dr. Roger Jeffs, Chief Executive Officer, and Micheal Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an overview and update on the company's business during a fireside chat session at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, beginning at 1:30 p.m. Eastern Time.

Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.09 per share a year ago.

MORRISVILLE, N.C., March 06, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2023 financial results on Wednesday, March 13, 2024. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update.

United Therapeutics said on Wednesday it has commenced litigation with the U.S. FDA for allowing an application for a drug by Liquidia Corp to treat a type of blood vessel disorder.

Liquidia's stock has increased in value by 209.32% since June 2022. Liquidia's PAH drug, Yutrepia, is expected to launch in the first or second quarter of 2024, potentially leading to profitability. Liquidia has gained a major partnership for a sustained-release inhaled Treprostinil product, which could compete with United Therapeutics' revenue products.

The average of price targets set by Wall Street analysts indicates a potential upside of 71.4% in Liquidia Technologies, Inc. (LQDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The U.S. Food and Drug Administration extended the review of Liquidia Corp's drug for the treatment of a progressive blood vessel disorder related to a lung condition, the company said on Thursday.

The consensus price target hints at a 29.9% upside potential for Liquidia Technologies, Inc. (LQDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Chris DeMuth Jr. discusses his position in uranium and his belief that nuclear energy will play a significant role in the future of energy production. He also updates us on SHF Holdings, a fintech company serving the cannabis industry, and predicts its growth potential in the coming years.

MORRISVILLE, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, beginning at approximately 11:15 a.m. Pacific Time (2:15 p.m. Eastern Time) at the Westin St. Francis in San Francisco, California.